These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18031724

  • 1. Tolterodine does not affect memory assessed by passive-avoidance response test in mice.
    Cappon GD, Bush B, Newgreen D, Finch GL, Alper RH.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):225-8. PubMed ID: 18031724
    [Abstract] [Full Text] [Related]

  • 2. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S.
    Eur J Pharmacol; 2006 Jan 04; 529(1-3):157-63. PubMed ID: 16316647
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S.
    J Urol; 2007 Feb 04; 177(2):766-70. PubMed ID: 17222678
    [Abstract] [Full Text] [Related]

  • 4. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.
    Suzuki M, Noguchi Y, Okutsu H, Ohtake A, Sasamata M.
    Eur J Pharmacol; 2007 Feb 28; 557(2-3):154-8. PubMed ID: 17207478
    [Abstract] [Full Text] [Related]

  • 5. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
    Yusup A, Akino H, Miwa Y, Oyama N, Aoki Y, Ito H, Tanase K, Matsuta Y, Nakai M, Yokoyama O.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):143-9. PubMed ID: 17904547
    [Abstract] [Full Text] [Related]

  • 6. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S.
    J Clin Pharmacol; 2005 Aug 22; 45(8):961-8. PubMed ID: 16027408
    [Abstract] [Full Text] [Related]

  • 7. Tolterodine extended-release for overactive bladder.
    Chung DE, Te AE.
    Expert Opin Pharmacother; 2009 Sep 22; 10(13):2181-94. PubMed ID: 19663610
    [Abstract] [Full Text] [Related]

  • 8. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder.
    Sun F, Sui C, Zhou Y, Liu X, Shi Y, Wu Y, Li Y.
    Int J Pharm; 2013 Sep 15; 454(1):532-8. PubMed ID: 23891744
    [Abstract] [Full Text] [Related]

  • 9. Tolterodine for the treatment of overactive bladder.
    Salvatore S, Serati M, Bolis P.
    Expert Opin Pharmacother; 2008 May 15; 9(7):1249-55. PubMed ID: 18422481
    [Abstract] [Full Text] [Related]

  • 10. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs.
    Andersson SH, Lindgren A, Postlind H.
    Drug Metab Dispos; 1998 Jun 15; 26(6):528-35. PubMed ID: 9616187
    [Abstract] [Full Text] [Related]

  • 11. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K, Jaeger K, Wollny A, Penzel T, Fietze I, Roots I.
    Sleep Med; 2008 Jul 15; 9(5):579-82. PubMed ID: 17921051
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
    Påhlman I, Kankaanranta S, Palmér L.
    Arzneimittelforschung; 2001 Feb 15; 51(2):134-44. PubMed ID: 11258043
    [Abstract] [Full Text] [Related]

  • 13. Gomisin A improves scopolamine-induced memory impairment in mice.
    Kim DH, Hung TM, Bae KH, Jung JW, Lee S, Yoon BH, Cheong JH, Ko KH, Ryu JH.
    Eur J Pharmacol; 2006 Aug 07; 542(1-3):129-35. PubMed ID: 16824513
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of the ameliorating effect on learning and memory impairment and antinociceptive effect of KT-95 in mice.
    Hiramatsu M, Mizuno N, Kanematsu K.
    Behav Brain Res; 2006 Feb 28; 167(2):219-25. PubMed ID: 16223533
    [Abstract] [Full Text] [Related]

  • 15. Effects of an aqueous extract of Puerariae flos (Thomsonide) on impairment of passive avoidance behavior in mice.
    Yamazaki T, Yaguchi M, Nakajima Y, Hosono T, Niiho Y, Hibi Y, Kinjo J, Nohara T.
    J Ethnopharmacol; 2005 Sep 14; 100(3):244-8. PubMed ID: 16125021
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
    Simon HU, Malhotra B.
    Swiss Med Wkly; 2009 Mar 07; 139(9-10):146-51. PubMed ID: 19145494
    [Abstract] [Full Text] [Related]

  • 17. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.
    Påhlman I, d'Argy R, Nilvebrant L.
    Arzneimittelforschung; 2001 Feb 07; 51(2):125-33. PubMed ID: 11258042
    [Abstract] [Full Text] [Related]

  • 18. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J.
    Clin Pharmacol Ther; 1998 May 07; 63(5):529-39. PubMed ID: 9630826
    [Abstract] [Full Text] [Related]

  • 19. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
    Oishi M, Chiba K, Malhotra B, Suwa T.
    Drug Metab Dispos; 2010 Sep 07; 38(9):1456-63. PubMed ID: 20530222
    [Abstract] [Full Text] [Related]

  • 20. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep 07; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.